Adaptimmune Therapeutics (NASDAQ:ADAP) Announces Earnings Results

Adaptimmune Therapeutics (NASDAQ:ADAP) issued its earnings results on Monday. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09), Zacks reports. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.

Adaptimmune Therapeutics Stock Performance

Shares of NASDAQ ADAP opened at $0.28 on Tuesday. The company has a market cap of $70.83 million, a PE ratio of -1.26 and a beta of 2.52. The firm’s 50-day moving average price is $0.53 and its 200-day moving average price is $0.69. Adaptimmune Therapeutics has a 52-week low of $0.26 and a 52-week high of $1.65. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62.

Analyst Ratings Changes

ADAP has been the topic of several recent analyst reports. Scotiabank cut their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a report on Friday. Wells Fargo & Company lowered their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research note on Friday. Mizuho lowered their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Finally, StockNews.com assumed coverage on Adaptimmune Therapeutics in a report on Friday. They set a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Adaptimmune Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $2.18.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.